www.zdf.de
EU lässt Alzheimer-Medikament Leqembi nicht zu
Die europäische Arzneimittelbehörde EMA lässt das Alzheimer-Medikament Leqembi nicht für Europa zu. Nebenwirkungen seien zu schwerwiegend.
#Leqembi is an active hashtag on Bluesky. In the last 30 days, 6 people shared 23 posts with it — around 1 a day. Activity is down 100% versus the previous week, peaking on Jul 18 with 10 posts.
www.zdf.de
EU lässt Alzheimer-Medikament Leqembi nicht zu
Die europäische Arzneimittelbehörde EMA lässt das Alzheimer-Medikament Leqembi nicht für Europa zu. Nebenwirkungen seien zu schwerwiegend.
www.nytimes.com
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
www.beingpatient.com
‘Mission Critical’: Why the FDA Approved an Alzheimer’s Drug Update During Comms Freeze
When Eisai announced in a press release this week that they’d secured FDA approval for an Alzheimer’s drug dosage change, it seemed like a break in the Trump administration’s blanket freezes placed on...
youtu.be
Trump’s Health FALLS APART Fast AND Congress WANTS ANSWERS
YouTube video by MeidasTouch
third-news.com
Leqembi® Sales Surge to 29.3 Billion Yen in Q2 2026 Revealing Strong Market Demand
BioArctic AB's partner Eisai reports impressive sales growth of Leqembi® in Q2 2026, showcasing increased global demand for Alzheimer's treatment.
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
www.ipharmacenter.com
Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter
Leqembi Real-World LEADER Study validates the Real-World Performance New interim findings from the LEADER study, a three-year retrospective analysis of Leqembi (lecanemab), indicate sustained therapeu...
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.